Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer

By sjmartinez • December 20, 2023

Wang R, Mi Y, Ni J, Wang Y, Ding L, Ran X, Sun Q, Tan SY, Koeffler HP, Feng N, Chen YQ. Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer. Adv Sci (Weinh). 2023 Dec 20:e2304939. doi: 10.1002/advs.202304939. Epub ahead of print. PMID: 38115765.

Tags: castration-resistant prostate cancer, Cedars Sinai DoM, Drug-tolerant persister, Hematology/Oncology, peroxiredoxin 5, polaprezinc, Publications, stachyose

Related Posts

A qualitative analysis of post-hoc interviews with multilevel participants of a randomized controlled trial of a community-based intervention

Kohrman N, Rashid M, Flores R, Blyler C, Barragan NC, Kuo T, Inkelas M, Chen S, Rader F, Cheng S, Albert C, Bello NA, Ebinger[...]

Gut microbiota, blood metabolites, and left ventricular diastolic dysfunction in US Hispanics/Latinos

Luo K, Taryn A, Moon EH, Peters BA, Solomon SD, Daviglus ML, Kansal MM, Thyagarajan B, Gellman MD, Cai J, Burk RD, Knight R, Kaplan[...]

Left ventricular global longitudinal strain is worse in BRCA mutation positive breast cancer patients prior to cancer treatment and premature menopause

Lin B, LeVee A, Cao L, Basho R, Tamarappoo B, Wei J, Shufelt C. Left ventricular global longitudinal strain is worse in BRCA mutation positive[...]